NEW YORK (GenomeWeb) – OneOme and Rainbow Genomics today announced a deal to provide OneOme's RightMed pharmacogenomic test with Rainbow Genomics' whole-exome sequencing test services to patients in Hong Kong, Japan, and Macau.

The full OneOme RightMed platform will be offered by Rainbow to patients and physicians, the firms added.

Financial and other terms of the deal were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.